UNNECESSARY TESTS AND TREATMENTS IN LOW VALUE CRITICAL CARE
Dr Gerben Keijzers
Senior Staff Specialist Emergency Physician,
Gold Coast Hospital at Department of Health, Queensland &
Adjunct Professor, Honorary Professor of Emergency Medicine
Griffith University & Bond University,
Queensland, Australia
RESEARCHER PROFILE
Filmed in Southport, Queensland | January 2025
Dr Gerben Keijzers is a Senior Staff Specialist Emergency Physician at the Gold Coast University Hospital Emergency Department. Dr Keijzers balances half of his time between clinical work and academic duties, including teaching medical students and conducting research. His role also include being an honorary professor of emergency medicine at Bond University and is an associate professor at Griffith University.
Dr Keijzers completed a master’s degree in epidemiology and medical degree in Nijmegen, The Netherlands. He came to Australia in 2002 and completed his Fellowship in Emergency Medicine in 2008. He has a PhD in the quality of trauma care.
He works clinically, conducts clinical research and is a clinical supervisor for medical students on emergency medicine rotation. Over the past 15 years, Dr Keijzers has helped create seven research pillars focused on critical care studies, such as sepsis and antimicrobial stewardship.
His research focus includes low-value care, which is in the area of unnecessary tests and treatments with minimal benefits. Dr Keijzers has contributed to over 100 publications and more than 20 grant applications. Through his involvement in multi-site collaborative research projects, he encourages critical thinking and curiosity among clinical staff, striving to enhance both patient care and the efficiency of healthcare resources.
He is the former chair of the Queensland Emergency Research Collaborative, a member of the Clinical Trials Group of the Australasian College for Emergency Medicine, a member of the Research Advisory Committee for the Emergency Care Institute and is section editor for the peer-reviewed journal Emergency Medicine Australasia.
Note: Narrative adapted from University of Queensland website and interview
-
Life-changing donor milk for preterm babies
Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.
Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Interventions for improving outcomes of children who are deaf or hard of hearing
Professor Teresa Ching is a Conjoint Professor at NextSense Institute and Macquarie University, and an Honorary Professor at the University of Queensland in Australia. Her current research focuses on devising culturally sensitive practices in early detection and intervention to maximise children’s outcomes. Working with international colleagues, her current research is also directed towards developing global guidelines and recommendations for hearing screening beyond the newborn period, so that all children can benefit from early detection and intervention. The ultimate goal is to attain equity of care and outcomes for all children with hearing difficulties.
